Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


05.11.2018

1 Ann Surg Oncol
1 Biochem Biophys Res Commun
1 Biomed Pharmacother
1 BMJ Case Rep
1 Br J Cancer
1 Br J Radiol
1 Br Med Bull
2 Cancer Sci
2 Cent European J Urol
1 Curr Urol Rep
1 Diabet Med
1 Dis Markers
1 Eur J Surg Oncol
3 Eur Urol
1 Front Oncol
1 Hinyokika Kiyo
1 In Vivo
1 Int J Mol Med
1 Int J Mol Sci
1 Int J Oncol
1 Int J Paleopathol
1 J Cancer Res Ther
1 J Cell Biochem
1 J Egypt Natl Canc Inst
1 Lakartidningen
1 Mol Cancer Ther
1 Nanoscale Res Lett
1 Prog Urol
2 Sichuan Da Xue Xue Bao Yi Xue Ban
1 Ther Apher Dial
1 Urol Int
1 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. FUKUMOTO K, Kikuchi E
    ASO Author Reflections: PD-1 Expression in Bacillus Calmette-Guerin-Relapsing Bladder Cancer.
    Ann Surg Oncol. 2018 Oct 26. pii: 10.1245/s10434-018-6949.
    PubMed     Text format    


    Biochem Biophys Res Commun

  2. JIN B, Gong Y, Li H, Jiao L, et al
    C/EBPbeta promotes the viability of human bladder cancer cell by contributing to the transcription of bladder cancer specific lncRNA UCA1.
    Biochem Biophys Res Commun. 2018 Oct 27. pii: S0006-291X(18)32330.
    PubMed     Text format     Abstract available


    Biomed Pharmacother

  3. ZHANG Y, Zhang D, Lv J, Wang S, et al
    MiR-125a-5p suppresses bladder cancer progression through targeting FUT4.
    Biomed Pharmacother. 2018;108:1039-1047.
    PubMed     Text format     Abstract available


    BMJ Case Rep

  4. TASLEEM AM, Grouse ED, Almushatat A
    Keratinising squamous cell metaplasia: when is it safe to stop looking?
    BMJ Case Rep. 2018;2018.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. AVGERIS M, Tsilimantou A, Levis PK, Tokas T, et al
    Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.
    Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0320.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. ZHENG W, Chen K, Peng C, Yin SH, et al
    Contrast-enhanced ultrasonography versus MRI for evaluation of local invasion by cervical cancer.
    Br J Radiol. 2018 Jul 20:20170858. doi: 10.1259/bjr.20170858.
    PubMed     Text format     Abstract available


    Br Med Bull

  7. CRABB SJ, Douglas J
    The latest treatment options for bladder cancer.
    Br Med Bull. 2018 Oct 29. pii: 5146185. doi: 10.1093.
    PubMed     Text format     Abstract available


    Cancer Sci

  8. USUBA W, Urabe F, Yamamoto Y, Matsuzaki J, et al
    Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer.
    Cancer Sci. 2018 Nov 1. doi: 10.1111/cas.13856.
    PubMed     Text format     Abstract available

  9. YANG C, Wu S, Wu X, Zhou X, et al
    Silencing Circular RNA UVRAG Inhibits Bladder Cancer Growth and Metastasis via Targeting the miR-223/FGFR2 Axis.
    Cancer Sci. 2018 Nov 2. doi: 10.1111/cas.13857.
    PubMed     Text format     Abstract available


    Cent European J Urol

  10. MARCHEWKA Z, Szymanska B, Dembowski J, Dlugosz A, et al
    Low molecular weight proteins and enzymes in the urine of patients with bladder cancer - a pilot study.
    Cent European J Urol. 2018;71:280-286.
    PubMed     Text format     Abstract available

  11. DANGI AD, Kumar RM, Kodiatte TA, Gowri M, et al
    Is there a role for second transurethral resection in pTa high-grade urothelial bladder cancer?
    Cent European J Urol. 2018;71:287-294.
    PubMed     Text format     Abstract available


    Curr Urol Rep

  12. GORE JL
    Patient-Centered Outcomes in Bladder Cancer.
    Curr Urol Rep. 2018;19:105.
    PubMed     Text format     Abstract available


    Diabet Med

  13. RIPAMONTI E, Azoulay L, Abrahamowicz M, Platt RW, et al
    A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
    Diabet Med. 2018 Oct 30. doi: 10.1111/dme.13854.
    PubMed     Text format     Abstract available


    Dis Markers

  14. INAMOTO T, Uehara H, Akao Y, Ibuki N, et al
    A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
    Dis Markers. 2018;2018:5468672.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  15. SIRACUSANO S, D'Elia C, Cerruto MA, Gacci M, et al
    Quality of life following urinary diversion: Orthotopic ileal neobladder versus ileal conduit. A multicentre study among long-term, female bladder cancer survivors.
    Eur J Surg Oncol. 2018 Oct 21. pii: S0748-7983(18)31464.
    PubMed     Text format     Abstract available


    Eur Urol

  16. CHOI W, McConkey DJ
    ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers.
    Eur Urol. 2018 Oct 23. pii: S0302-2838(18)30732.
    PubMed     Text format    

  17. GEYNISMAN DM, Abbosh PH, Plimack ER, Zibelman M, et al
    Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Eur Urol. 2018;73:760-762.
    PubMed     Text format    

  18. PEEKER R
    Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification.
    Eur Urol. 2018;73:809-810.
    PubMed     Text format    


    Front Oncol

  19. GIULIETTI M, Occhipinti G, Righetti A, Bracci M, et al
    Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.
    Front Oncol. 2018;8:450.
    PubMed     Text format     Abstract available


    Hinyokika Kiyo

  20. KIMURA H, Uemura Y, Megumi Y, Fukuzawa S, et al
    [A Case of PT1 Plasmacytoid Variant Bladder Cancer Treated by Bladder Conserving Therapy].
    Hinyokika Kiyo. 2018;64:369-372.
    PubMed     Text format     Abstract available


    In Vivo

  21. LIAO CH, Chang WS, Tsai CW, Hu PS, et al
    Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer.
    In Vivo. 2018;32:1045-1050.
    PubMed     Text format     Abstract available


    Int J Mol Med

  22. LIU Y, Gao S, Du Q, Zhao Q, et al
    Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis.
    Int J Mol Med. 2018 Oct 29. doi: 10.3892/ijmm.2018.3959.
    PubMed     Text format     Abstract available


    Int J Mol Sci

  23. ECKSTEIN M, Wirtz RM, Gross-Weege M, Breyer J, et al
    mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.
    Int J Mol Sci. 2018;19.
    PubMed     Text format     Abstract available


    Int J Oncol

  24. AZUMA H, Inamoto T, Takahara K, Ibuki N, et al
    Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
    Int J Oncol. 2018 Nov 2. doi: 10.3892/ijo.2018.4619.
    PubMed     Text format     Abstract available


    Int J Paleopathol

  25. BIEHLER-GOMEZ L, Giordano G, Cattaneo C
    The overlooked primary: bladder cancer metastases on dry bone. A study of the 20th century CAL Milano Cemetery Skeletal Collection.
    Int J Paleopathol. 2018;24:130-140.
    PubMed     Text format     Abstract available


    J Cancer Res Ther

  26. SETH N, Gandhi JS, Pasricha S, Mehta A, et al
    Nasopharyngeal carcinoma with unusual metastasis to urinary bladder.
    J Cancer Res Ther. 2018;14:1160-1161.
    PubMed     Text format     Abstract available


    J Cell Biochem

  27. ZHANG J, Song N, Duan Z
    Rs6265 polymorphism in brain-derived neurotrophic factor (Val/Val and Val/Met) promotes proliferation of bladder cancer cells by suppressing microRNA-205 and enhancing expression of cyclin J.
    J Cell Biochem. 2018 Nov 1. doi: 10.1002/jcb.28004.
    PubMed     Text format     Abstract available


    J Egypt Natl Canc Inst

  28. MOEEN AM, Safwat AS, Gadelmoula MM, Moeen SM, et al
    Health related quality of life after urinary diversion. Which technique is better?
    J Egypt Natl Canc Inst. 2018;30:93-97.
    PubMed     Text format     Abstract available


    Lakartidningen

  29. HOLMANG S, Hedelin H

    Lakartidningen. 2018;115.
    PubMed     Text format    


    Mol Cancer Ther

  30. MARTIN DT, Shen H, Steinbach-Rankins JM, Zhu X, et al
    Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target.
    Mol Cancer Ther. 2018 Oct 31. pii: 1535-7163.MCT-17-1079.
    PubMed     Text format     Abstract available


    Nanoscale Res Lett

  31. TAO X, Tao T, Wen Y, Yi J, et al
    Novel Delivery of Mitoxantrone with Hydrophobically Modified Pullulan Nanoparticles to Inhibit Bladder Cancer Cell and the Effect of Nano-drug Size on Inhibition Efficiency.
    Nanoscale Res Lett. 2018;13:345.
    PubMed     Text format     Abstract available


    Prog Urol

  32. ROUPRET M, Neuzillet Y, Pignot G, Comperat E, et al
    [French ccAFU guidelines on bladder cancer - Update 2018-2020: Bladder cancer].
    Prog Urol. 2018 Oct 23. pii: S1166-7087(18)30461.
    PubMed     Text format     Abstract available


    Sichuan Da Xue Xue Bao Yi Xue Ban

  33. HE QY, Deng S, Liao BH, Deng L, et al
    [Risk Factors for Wound Healing of Infective Surgical Incision after Radical Cystectomy in Patients of Muscle Invasive Bladder Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2018;49:640-644.
    PubMed     Text format     Abstract available

  34. BAI YJ, Wang XM, Han P, Yang YB, et al
    [Influence of Renin-angiotensin System Blockage on Recurrence of Non-muscle-invasive Bladder Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2018;49:635-639.
    PubMed     Text format     Abstract available


    Ther Apher Dial

  35. OGASAWARA M, Miyashita M, Ota S
    Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses.
    Ther Apher Dial. 2018;22:266-277.
    PubMed     Text format     Abstract available


    Urol Int

  36. LAUSENMEYER EM, Braun K, Breyer J, Gierth M, et al
    Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.
    Urol Int. 2018 Nov 1:1-6. doi: 10.1159/000493577.
    PubMed     Text format     Abstract available


    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

  37. SHI J, Gao B, Yang Y, Yang L, et al
    [Influence of perioperative leukodeplated red blood cell transfusion on immune function of patients with bladder cancer].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34:632-636.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: